WFG Advisors’s Celldex Therapeutics CLDX Stock Holding History

WFG Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$1K	Hold	33	–	–	﹤0.01%	1471
2017 Q1	$2K	Hold	33	–	–	﹤0.01%	1331
2016 Q4	$2K	Hold	33	–	–	﹤0.01%	1404
2016 Q3	$2K	Hold	33	–	–	﹤0.01%	1388
2016 Q2	$2K	Hold	33	–	–	﹤0.01%	1367
2016 Q1	$2K	Hold	33	–	–	﹤0.01%	1327
2015 Q4	$8K	Hold	33	–	–	﹤0.01%	1122
2015 Q3	$5K	Hold	33	–	–	﹤0.01%	1248
2015 Q2	$13K	Hold	33	–	–	﹤0.01%	1104
2015 Q1	$14K	Hold	33	–	–	﹤0.01%	1091
2014 Q4	$9K	Hold	33	–	–	﹤0.01%	1491
2014 Q3	$6K	Buy	33 +13	+65%	+$2.83K	﹤0.01%	1611
2014 Q2	$5K	Hold	20	–	–	﹤0.01%	1648
2014 Q1	$5K	Buy	+20	New	+$7.66K	﹤0.01%	1612

Other funds holding CLDX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

KLP Enterprises Branford, Connecticut $1.97M AUM

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

WFG Advisors's CLDX Position: Q2 2017 in Review

WFG Advisors held its Celldex Therapeutics (CLDX) position steady in Q2 2017 at 33 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1471.

WFG Advisors first reported a position in CLDX in Q1 2014 and has held it in 14 quarters since. The position peaked at $14K in Q1 2015. 130 funds tracked by Wall St. Rank hold CLDX as of Q2 2017.

WFG Advisors held 33 shares of Celldex Therapeutics worth $1K as of Q2 2017.
WFG Advisors left its Celldex Therapeutics share count unchanged in Q2 2017.
Celldex Therapeutics made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1471 holding.
WFG Advisors first reported a position in Celldex Therapeutics in Q1 2014 and has held it in 14 quarters since.
WFG Advisors's Celldex Therapeutics position peaked at $14K in Q1 2015.
130 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.